AbbVie is heralding positive new data on its hepatitis C cocktail, touting the treatment's benefit in some tough-to-treat patients as it prepares for a head-to-head competition with market leader Gilead Sciences.
Merck & Co. just disclosed some welcome news for its own investors--and potentially for competitors, too. Not to mention all the market watchers ready for the long IMPROVE-IT trial saga to come to an end.
The DNA Medicine Institute, developer of a diagnostic device that can perform hundreds of clinical lab tests with a single drop of blood, won the Nokia Sensing Xchallenge for promising medical sensing technologies.
Microsoft engineers have developed a 3-D audio system that can help the visually impaired move about on city streets and within their homes with greater ease using Bluetooth technology.
In 2003, a team of scientists and IT engineers set out to create a map of which proteins are found in each part of the body. Now, after committing more than 1,000 man years to the project, the team has released the Human Protein Atlas, an interactive map of the proteome containing 13 million annotated images.
As the med tech industry casts its eye toward quick, point-of-care diagnostics, scientists at MIT are teaming up with physicians from Harvard Medical School to create new technology that could help distinguish between acute emphysema and heart failure by measuring an individual's breath.
Amid efforts to quell the growing Ebola epidemic, scientists, companies and health officials are teaming up to develop innovative medical devices to treat the deadly disease.
Fremont, CA's Shockwave Medical released clinical trial data at the Vascular Interventional Advances Annual Conference in Las Vegas that it says demonstrate the effectiveness of its investigational Lithoplasty balloon catheters at treating peripheral artery disease.
Drones are used to kill bad guys in war zones, but graduate student Alex Momont wants to use them to save lives. He has developed a prototype drone capable of flying to the rescue of heart attack victims by delivering a defibrillator to the site much faster than an ambulance.
Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises a permanent solution some rare eye diseases.